Data from European Association of Urology (EAU) - Curated by EPG Health - Last updated 11 July 2019

Status

live

Latest update

01-Mar-19

The European Association of Urology (EAU) Guidelines Group for Prostate Cancer have prepared this guidelines document to assist medical professionals assess the evidence-based management of prostate cancer (PCa). The multidisciplinary guidelines panel includes urologists, radiation oncologists, a medical oncologist, a radiologist and a pathologist.

Read full guideline

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

Hereditary ATTR amyloidosis

Hereditary ATTR amyloidosis

Explore the pathophysiology, epidemiology and multi-system symptoms associated with hereditary ATTR amyloidosis, as well as how to achieve an early and accurate diagnosis.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Load more

Related Content

News

PROSPER trial protocol of Xtandi (enzalutamide) in patients with non-metastatic castration-resistant prostate cancer is amended.- Astellas and Pfizer

Astellas Pharma Inc. and Pfizer Inc.announced the amendment of the protocol for the registrational PROSPER trial, a multi-national, randomized, double-blind,...

Added 2 years ago

Phase III LATITUDE clinical trial shows Zytiga (abiraterone acetate) plus prednisone shows impressive improvement in survival in metastatic prostate cancer- Janssen R&D

Janssen Research & Development announced data from the pivotal phase III LATITUDE clinical trial, which showed Zytiga (abiraterone acetate) plus...

Added 2 years ago

Prolaris test accurately predicts the 10-year risk of metastases in men treated for prostate cancer.- Myriad Genetics Inc.

- Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, announced new data demonstrating the utility of the...

Added 2 years ago

Myovant initiates Phase III HERO trial of relugolix to treat advanced prostate cancer-

Myovant Sciences announced it has initiated a Phase III clinical trial, HERO , to evaluate the safety and efficacy of...

Added 2 years ago

Phase III data on FP 001 (leuprolide mesylate injectable suspension) in prostate cancer- Foresee Pharmaceuticals

Foresee Pharmaceuticals has announced the top-line result of FP 001 (leuprolide mesylate injectable suspension) 50mg phase III clinical trial, an...

Added 2 years ago

Load more

View all 10908 News items
Journal articles

Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer.

Objective: To investigate gut bacterial diversity, identify specific metabolic pathways associated with disease, and develop a microbiome risk profile for prostate cancer.

Added 3 months ago

The Role of Gut Microbiome in the Pathogenesis of Prostate Cancer: A Prospective, Pilot Study.

Objective: To elucidate potential biomarkers or mechanistic principles involved with the gut microbiota and its impact on prostate cancer pathogenesis.

Added 3 months ago

Apalutamide and its use in the treatment of prostate cancer.

High-risk nonmetastatic castration-resistant prostate cancer is a lethal disease that previously lacked clear treatment options. Progression to bone metastases is associated with significant morbidity and high cost.

Added 3 months ago

Metastatic prostate cancer remains incurable, why?

Metastatic prostate cancer patients present in two ways-with already disseminated disease at the time of presentation or with disease recurrence after definitive local therapy. Androgen deprivation therapy is given as the most...

Added 3 months ago

Apalutamide: Emerging Therapy for Non-Metastatic Castration-Resistant Prostate Cancer.

Prostate cancer is the second deadliest cancer in the US and the fourth most common cancer among Saudi males. Patients usually present with non-metastatic disease and treated with localized therapy.

Added 3 months ago

Load more

View all 13526 Journal articles items
Clinical trials

Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. (PCM301)

The aims of this study are:
- to assess the impact of TOOKAD® Soluble-Vascular Targeted Photodynamic Therapy (VTP) on the rate of absence of definite cancer using patients on active surveillance as a comparison...

Added 9 years ago

A Study of Definitive Therapy to Treat Prostate Cancer (oligo-mets)

To assess the safety of treating men with oligometastatic prostate cancer with the following therapy: (1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of neoadjuvant androgen deprivation and up to 6 cycles...

Added 3 months ago

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer...

Added 3 months ago

Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

The purpose of the phase 2 study is to determine whether Onvansertib given orally once daily for 5 consecutive days every 21 days is safe and tolerable in adult patients with Metastatic Castration-Resistant Prostate Cancer who...

Added 3 months ago

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate and prednisone (AA-P) compared to AA-P plus placebo.

Added 3 months ago

Load more

View all 7642 Clinical trials items